Get the Stockscreener App
45.00
4.44%
-2.09
Terns Pharmaceuticals Inc stock is traded at $45.00, with a volume of 6.88M.
It is down -4.44% in the last 24 hours and up +121.67% over the past month.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
See More
Previous Close:
$47.09
Open:
$46.98
24h Volume:
6.88M
Relative Volume:
2.02
Market Cap:
$4.05B
Revenue:
-
Net Income/Loss:
$-95.90M
P/E Ratio:
-34.09
EPS:
-1.32
Net Cash Flow:
$-79.09M
1W Performance:
+53.27%
1M Performance:
+121.67%
6M Performance:
+1,045%
1Y Performance:
+582.85%
1-Day Range:
$44.50
$47.13
1-Week Range:
$30.12
$48.26
52-Week Range:
$1.865
$48.26
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Name
Terns Pharmaceuticals Inc
Sector
Industry
Phone
650-525-5535 EXT.101
Address
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Compare TERN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
45.00 | 4.24B | 0 | -95.90M | -79.09M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-03-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-04-25 | Resumed | H.C. Wainwright | Neutral |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Oct-31-24 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Mizuho | Buy |
| Jun-07-23 | Initiated | Jefferies | Buy |
| May-31-23 | Initiated | ROTH MKM | Buy |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-14-23 | Initiated | JMP Securities | Mkt Outperform |
| Feb-07-23 | Initiated | UBS | Buy |
| Sep-12-22 | Initiated | H.C. Wainwright | Neutral |
| Sep-14-21 | Resumed | Goldman | Buy |
| Mar-02-21 | Initiated | Cowen | Outperform |
| Mar-02-21 | Initiated | Goldman | Buy |
| Mar-02-21 | Initiated | JP Morgan | Overweight |
View All
Terns Pharmaceuticals Inc Stock (TERN) Latest News
Pharmaceutical Stocks To Follow TodayDecember 10th - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Terns Pharmaceutical prices stock at $40 per share - MSN
Terns Pharmaceuticals raises $747.5 million in public offering - Investing.com
Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Citizens Analyst Raises Price Target for Terns Pharma (TERN) to $57.00 | TERN Stock News - GuruFocus
Terns Pharmaceuticals, Inc. Announces Upsized Public Offering - TradingView
Terns Pharmaceuticals stock price target raised to $57 from $35 at Citizens - Investing.com Canada
Terns Pharmaceuticals Stock Surge: Analyzing the Leap - StocksToTrade
Jefferies raises Terns Pharmaceuticals stock price target to $70 on CML data - Investing.com Canada
Terns Pharmaceuticals Stock Soars After Leukemia Drug Delivers Big Early Responses In Tough-To-Treat Patients - Stocktwits
Terns Pharmaceuticals Stock Soars Amid Promising Drug Trial - TipRanks
TERN Upsizes Stock Offering to $502M - GuruFocus
Terns Pharmaceuticals (TERN) Announces Upsized Public Offering - GuruFocus
Why Terns Pharmaceuticals (TERN) Is Up 54.9% After Upsized $650 Million Equity Raise Following TERN-701 Data - Yahoo Finance
Terns Pharmaceuticals proposes $400M equity offering - MSN
Terns Pharmaceuticals Prices Upsized $650 Million Common Stock Offering - marketscreener.com
Terns Pharmaceuticals prices upsized $650 million public offering By Investing.com - Investing.com Nigeria
Terns Pharmaceuticals (TERN): Reassessing Valuation After CARDINAL CML Data Fuels Sharp Share Price Surge - Yahoo Finance
Terns Pharmaceuticals prices upsized $650 million public offering - Investing.com
Terns announces pricing of upsized $650 million public offering at $40 per share - marketscreener.com
Terns Announces Pricing of Upsized $650 Million Public Offering | Associated Press | syndication news - Enidnews.com
Terns Announces Pricing of Upsized $650 Million Public Offering - GlobeNewswire Inc.
Terns Pharmaceuticals Stock Skyrockets: Should You Dive In? - StocksToTrade
BMO Capital Maintains Terns Pharmaceuticals (TERN) Outperform Recommendation - Nasdaq
Terns (TERN) hits all-time high on stellar leukemia treatment results - MSN
Terns (TERN) Hits All-Time High on Stellar Leukemia Treatment Results - Finviz
Terns Pharmaceuticals: CML Data Blows Wall Street AwayAgain (NASDAQ:TERN) - Seeking Alpha
Oppenheimer Raises TERN Price Target by 107% to $58 | TERN Stock News - GuruFocus
Terns Pharma (TERN) Analyst Rating Update: Price Target Raised b - GuruFocus
Barclays Raises Terns Pharma (TERN) Price Target to $56 | TERN Stock News - GuruFocus
Terns Pharmaceuticals price target raised to $56 from $35 at Truist - TipRanks
Terns Pharmaceuticals stock rating reiterated by BMO Capital with $54 target - Investing.com South Africa
Terns Pharmaceuticals (TERN) Announces $400M Public Offering Pla - GuruFocus
Mizuho Raises Terns Pharma (TERN) Price Target to $54, Maintains Outperform Rating | TERN Stock News - GuruFocus
Oppenheimer Adjusts PT on Terns Pharmaceuticals to $58 From $28, Maintains Outperform Rating - marketscreener.com
Broadcom To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Terns Pharmaceuticals price target raised to $58 from $28 at Oppenheimer - TipRanks
Terns Pharmaceuticals (TERN) Launches $400M Public Offering - GuruFocus
Terns Pharmaceuticals price target raised to $54 from $33 at Mizuho - TipRanks
Truist Raises Price Target on Terns Pharmaceuticals to $56 From $35, Keeps Buy Rating - marketscreener.com
Mizuho Raises Price Target on Terns Pharmaceuticals to $54 From $33, Keeps Outperform Rating - marketscreener.com
Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster - Benzinga
Terns Pharmaceuticals launches $400 million public offering By Investing.com - Investing.com Nigeria
H.C. Wainwright raises Terns Pharmaceuticals stock price target to $60 on CML drug data - Investing.com UK
Mizuho raises Terns Pharmaceuticals stock price target to $54 on CML drug data - Investing.com
Terns Pharma (TERN) Sees Price Target Raised by HC Wainwright | - GuruFocus
HC Wainwright & Co. Maintains Terns Pharmaceuticals (TERN) Buy Recommendation - Nasdaq
Terns Pharmaceuticals (TERN) Launches $400M Public Stock Offerin - GuruFocus
Terns Pharmaceuticals Launches $400 Million Public Offering - Nasdaq
Terns Announces Proposed Public Offering - The Manila Times
Terns Pharmaceuticals Inc Stock (TERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):